Tip os
Log ind
Hans Schambye - red.jpg
Foto: Hans Schambye

Complex study delays BMS’ decision on Galecto takeover

Top picks in English:

2016 will not be the year when Denmark’s Galecto learns whether or not Bristol-Myers Squibb will buy the biotech in a multi-million-dollar deal. CEO Hans Schambye has a good gut feeling, however, nothing is set in stone in the world of biotech.


BY LONNI LYNGE
Offentliggjort 26.10.16 kl. 16:38

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Zealand sees big potential for SBS drug

Britt.jpg Top picks in English:

Zealand Pharma sees a significant potential for the candidate drug glepaglutide for treatment of short bowel syndrome (SBS), which has just delivered promising phase II results. The biotech company plans to win approval and market the drug on its own, hoping it can compete with a similar product from Shire, says CEO Britt Meelby Jensen.

Lundbeck Foundation company goes public

Top picks in English:

Lundbeckfonden Ventures’ portfolio company Bonesupport has listed on the Swedish stock market and raised SEK 500 million (about USD 57 million). The IPO puts a period to a busy half year, where two other companies have been sold. New investments are coming up, says managing partner Mette Kirstine Agger.

Leo Pharma invests in US biotech company

Top picks in English:

The Danish dermatology company Leo Pharma has pumped money into a US based biotech company developing a medical device mainly to be used in treatments of a hair loss disease. It is also the first agreement made from Leo’s newly founded hub in Boston.

Onxeo raises EUR 15m in stock offering

Top picks in English:

The French-Danish biotech company Onxeo has raised EUR 15 million (USD 16.73 million) in a recently completed capital increase. The goal was EUR 12 million (USD 13.39 million), but the fundraising brought the company’s management a pleasant surprise.

Here is what Danish drug companies pay their workers

Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

IBM to develop artificial intelligence for Danish healthcare system

Top picks in English:

The Capital Region of Denmark has budgeted DKK 30 million (USD 4.53 million) for developing artificial intelligence to the public health authorities in collaboration with IBM.

Forsiden lige nu

Flere indberetter svigt ved medicoudstyr

35369814 - 28_05_2013 - Praktikant projekt - PEDERSEN MIKKEL BERG.jpg Medico & Rehab:

Der er flere og flere som indberetter problemer med medicoudstyr. Det fremgår af Lægemiddelstyrelsens årsrapport for området. Meget tilfredsstillende, lyder det fra styrelsen.

Forventningerne til det globale medicinsalg er faldende

Medicinal & Biotek:

En ny rapport fra EvaluatePharma viser, at forventningerne til det globale salg af lægemidler er faldet for første gang i et årti. Det skyldes en række faktorer, men primært et tiltagende prispres.

Nordea regner med kæmpe salg af Novos guldæg

Medicinal & Biotek:

Novo Nordisks lægemiddel semaglutid kan måske være selskabets nøgle til de mange milliarder, der ligger i medicinsk behandling af svær overvægt i USA. Det mener Nordeas medicinalanalytiker, der påpeger at de nye data for midlet kan være en game changer.

Cytovac gør klar til kapitalrejsning og første studiedata

Medicinal & Biotek:

Det danske biotekselskab Cytovac har for nylig rejst små 10 mio. kr., men der skal yderligere 50 mio. kr. i kassen inden udgangen af 2017, siger adm. direktør Martin Roland Jensen. Samtidig kan man, hvis alt går vel, forvente de første data fra et vigtigt fase 2-studie allerede i år.

Farmabranchen mest hadede mand varmer op til bedragerisag

Medicinal & Biotek:

Bedrageri-retssagen mod Martin Shkreli, den kontroversielle og excentriske forhenværende topchef fra Turing Pharmaceuticals, bliver i denne uge indledt under stor bevågenhed.

Novo indgår alliance om stop af fossile brændstoffer

Medicinal & Biotek:

En ny, tyve år lang aftale mellem Novo Nordisk og en række andre aktører skal sikre grøn forsyning til selskabets produktion.

ANNONCE
ANNONCE


ANNONCE